Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: Retrospective cohort study

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Weich, Scott ^a   Pearce, Hannah Louise ^b   Croft, Peter ^b   Singh, Swaran ^a   Crome, Ilana ^c   Bashford, James ^b   Frisher, Martin ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c Staffordshire and Stoke on Trent Partnership NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; DIAZEPAM; HYPNOTIC AGENT; TEMAZEPAM; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ADOLESCENT; ADULT; AGE; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; FEMALE; FOLLOW UP; GENDER; HAZARD RATIO; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED KINGDOM;

ANTI-ANXIETY AGENTS; BENZODIAZEPINES; FEMALE; GREAT BRITAIN; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; MORTALITY; PRESCRIPTION DRUGS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84897135239     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g1996     Document Type: Article

References (37)

1. Tsimtsiou Z, Ashworth M, Jones R. Variations in anxiolytic and hypnotic prescribing by GPs: a cross-sectional analysis using data from the UK Quality and Outcomes Framework. Br J Gen Pract 2009;59:e191-8.
2. NHS Prescription Services. Central nervous system national charts. NHS Business Services Authority, 2012.
3. Royal College of General Practitioners and Royal College of Psychiatrists. Addiction to medicines consensus statement 2013. www.rcgp.org.uk/news/2013/january/addiction-to-medicines-consensus-statement. aspx.
4. Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012;345:e8343.
5. Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005;331:1169.
6. Billioti de Gage S, Begaud B, Bazin F, Verdoux H, Dartigues J-F, Peres K, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012;345:e6231.
7. Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health 2012;66:869-73.
8. Wu CS, Ting TT, Wang SC, Chang IS, Lin KM. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry 2011;19:151-9.
9. Kripke DF. Chronic hypnotic use: deadly risks, doubtful benefit. Sleep Med Rev 2000;4:5-20. (Pubitemid 30187040)
10. Paterniti S, Dufouil C, Alpérovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 2002;22:285-93. (Pubitemid 34546844)
11. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004;18:37-48. (Pubitemid 38197758)
12. Kripke DF. Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry 2007;7:42.
13. Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995;5:239-44.
14. Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med 2013:1-8.
15. Kripke DF. Possibility that certain hypnotics might cause cancer in skin. J Sleep Res 2008;17:245-50.
16. Mallon L, Broman JE, Hetta J. Is usage of hypnotics associated with mortality? Sleep Med 2009;10:279-86.
17. Kao CH, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, et al. Benzodiazepine use possibly increases cancer risk: a population-based retrospective cohort study in Taiwan. J Clin Psychiatry 2012;73:e555-60.
18. Obiora E, Hubbard R, Sanders RD, Myles PR. The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. Thorax 2013;68:163-70.
19. Hausken AM, Skurtveit S, Tverdal A. Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. Pharmacoepidemiol Drug Saf 2007;16:913-8. (Pubitemid 47333543)
20. Belleville G. Mortality hazard associated with anxiolytic and hypnotic drug use in the national population health survey. Can J Psychiatry 2010;55:558-67.
21. Hartz A, Ross JJ. Cohort study of the association of hypnotic use with mortality in postmenopausal women. BMJ Open 2012:e001413.
22. Charlson F, Degenhardt L, McLaren J, Hall W, Lynskey M. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf 2009;18:93-103.
23. Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012:2:e000850.
24. Gisev N, Hartikainen S, Chen TF, Korhonen M, Bell JS. Mortality associated with benzodiazepines and benzodiazepine-related drugs among community-dwelling older people in Finland: a population-based retrospective cohort study. Can J Psychiatry 2011;56:377-81.
25. Vinkers DJ, Gussekloo J, Van der Mast RC, Zitman FG, Westendorp RGJ. Benzodiazepine use and risk of mortality in individuals aged 85 years or older. JAMA 2003;290:2942-3. (Pubitemid 37505522)
26. Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L. Mortality hazard associated with prescription hypnotics. Biol Psychiatry 1998;43:687-93. (Pubitemid 28222390)
27. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012;69:476-83.
28. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128-36.
29. BMA and Royal Pharmaceutical Society of Great Britain. British national formulary. 63 ed. BMJ Group and RPS Publishing, 2012.
30. Solomon MD, Majumdar SR. Primary non-adherence of medications: lifting the veil on prescription-filling behaviors. J Gen Internl Med 2010;25:280-1.
31. Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 2010;25:284-90.
32. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. WHO Collaborating Centre for Drug Statistics Methodology, 2011.
33. Savitz DA, Baron AE. Estimating and correcting for confounder misclassification. Am J Epidemiol 1989;129:1062-71. (Pubitemid 19123943)
34. Fewell Z, Davey Smith G, Sterne JAC. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol 2007;166:646-55. (Pubitemid 47347902)
35. Lawlor DA, Smith GD, Bruckdorfer KR, Kundu D, Ebrahim S. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet 2004;363:1724-7. (Pubitemid 38670332)
36. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010;340:b5087.
37. Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, et al. Illustrating bias due to conditioning on a collider. Int J Epidemiol 2010;39:417-20.